Janet Wittes
#89,257
Most Influential Person Now
American statistician
Janet Wittes's AcademicInfluence.com Rankings
Janet Wittesmathematics Degrees
Mathematics
#5884
World Rank
#8237
Historical Rank
Statistics
#499
World Rank
#575
Historical Rank
Download Badge
Mathematics
Why Is Janet Wittes Influential?
(Suggest an Edit or Addition)According to Wikipedia, Janet Turk Wittes is an American statistician known for her work on clinical trials. Education Wittes is the daughter of a chemist and a psychologist. She began her studies at Radcliffe College in the biochemistry program, choosing it over chemistry because of its added opportunities for mentorship. Her faculty mentor, John Tileston Edsall, noting her preference for inference over experiment, guided her to aim for a career in statistics. Towards this goal, she switched her major to mathematics, graduating in 1964.
Janet Wittes's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. (1999) (7676)
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure (2000) (5314)
- Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. (1999) (3049)
- Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial (1995) (2244)
- Cardiovascular Risk Associated With Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention (2005) (2002)
- Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials (2013) (1418)
- Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (1083)
- Celecoxib for the prevention of sporadic colorectal adenomas. (2006) (1030)
- Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. (2001) (952)
- Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. (1991) (911)
- Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial (1994) (889)
- Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial (2017) (861)
- Celecoxib for the prevention of colorectal adenomatous polyps. (2006) (804)
- Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. (2013) (796)
- Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. (2003) (723)
- Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. (1987) (594)
- Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. (1988) (536)
- Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. (2015) (490)
- Dietary trans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women. (1994) (466)
- Bardoxolone methyl and kidney function in CKD with type 2 diabetes. (2011) (456)
- Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. (2000) (435)
- The role of internal pilot studies in increasing the efficiency of clinical trials. (1990) (423)
- Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. (2001) (406)
- Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. (1999) (403)
- Cardiovascular Risk of Celecoxib in 6 Randomized Placebo-Controlled Trials: The Cross Trial Safety Analysis (2008) (349)
- Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification. (1988) (342)
- Blood Stage Malaria Vaccine Eliciting High Antigen-Specific Antibody Concentrations Confers No Protection to Young Children in Western Kenya (2009) (340)
- Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. (2006) (330)
- Through the looking glass: understanding non-inferiority (2011) (302)
- Effect of Celecoxib on Cardiovascular Events and Blood Pressure in Two Trials for the Prevention of Colorectal Adenomas (2006) (290)
- The B-value: a tool for monitoring data. (1988) (290)
- Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. (2001) (278)
- Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program. (1994) (278)
- Morphometric analysis of the composition of atherosclerotic plaques in the four major epicardial coronary arteries in acute myocardial infarction and in sudden coronary death. (1989) (274)
- Glucose and insulin responses to dietary chromium supplements: a meta-analysis. (2002) (265)
- Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. (1999) (249)
- Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure (2017) (248)
- Sample size calculations for randomized controlled trials. (2002) (245)
- Baseline Characteristics and Early Blood Pressure Control in the CONVINCE Trial (2001) (218)
- Surrogate endpoints in clinical trials: cardiovascular diseases. (1989) (216)
- Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. (2000) (214)
- Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial (2021) (201)
- Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. (2009) (188)
- Capture-recapture methods for assessing the completeness of case ascertainment when using multiple information sources. (1974) (188)
- Efficacy, Safety, and Durability of Voretigene Neparvovec-rzyl in RPE65 Mutation-Associated Inherited Retinal Dystrophy: Results of Phase 1 and 3 Trials. (2019) (171)
- Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand (1996) (167)
- Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. (2015) (160)
- Towards an RTS,S-based, multi-stage, multi-antigen vaccine against falciparum malaria: progress at the Walter Reed Army Institute of Research. (2005) (155)
- Use of a Highly Purified α1-Antitrypsin Standard to Establish Ranges for the Common Normal and Deficient α1-Antitrypsin Phenotypes (1991) (154)
- Change in physician perspective on cholesterol and heart disease. Results from two national surveys. (1987) (147)
- Randomized, Placebo-Controlled Trial of HA-1A, a Human Monoclonal Antibody to Endotoxin, in Children with Meningococcal Septic Shock (1999) (145)
- A generalization of the simple capture-recapture model with applications to epidemiological research. (1968) (144)
- Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis. (2020) (139)
- Increased sensitivity of the denervated transplanted human heart to isoprenaline both before and after beta-adrenergic blockade. (1987) (137)
- Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. (2014) (136)
- Change in cholesterol awareness and action. Results from national physician and public surveys. (1991) (129)
- Internal pilot studies II: comparison of various procedures. (1999) (127)
- Study design and rationale for the clinical outcomes of the STABILITY Trial (STabilization of Atherosclerotic plaque By Initiation of darapLadIb TherapY) comparing darapladib versus placebo in patients with coronary heart disease. (2010) (119)
- Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (119)
- Morphometric analysis of the composition of coronary arterial plaques in isolated unstable angina pectoris with pain at rest. (1990) (115)
- Rationale and design of the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (HIT) for secondary prevention of coronary artery disease in men with low high-density lipoprotein cholesterol and desirable low-density lipoprotein cholesterol. (1993) (104)
- A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adults. (2007) (102)
- Effects of margarine compared with those of butter on blood lipid profiles related to cardiovascular disease risk factors in normolipemic adults fed controlled diets. (1998) (100)
- Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. (2021) (100)
- Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with AS02A, in adults in western Kenya. (2007) (99)
- Cisplatin in the treatment of metastatic breast carcinoma A prospective randomized trial of two dosage schedules (1982) (97)
- Digitalis--a new controversy regarding an old drug. The pitfalls of inappropriate methods. (1986) (96)
- Spontaneous abortion as a screening device. The effect of fetal survival on the incidence of birth defects. (1975) (94)
- Internal pilot studies I: type I error rate of the naive t-test. (1999) (92)
- Plasma lipoprotein (a) levels in men and women consuming diets enriched in saturated, cis-, or trans-monounsaturated fatty acids. (1997) (91)
- Analysis as-randomized and the problem of non-adherence: an example from the Veterans Affairs Randomized Trial of Coronary Artery Bypass Surgery. (1993) (90)
- Rationale and design for the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) Trial. (1998) (89)
- Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative (1996) (88)
- Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina (2001) (83)
- Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis (2022) (80)
- Infectious disease testing for blood transfusions. (1995) (80)
- Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. (1991) (80)
- Rationale and Trial Design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: The Occurrence of Renal Events (BEACON) (2013) (79)
- Intensity of renal support in critically ill patients with acute kidney injury (New England Journal of Medicine (2008) 359, (7-20)) (2009) (77)
- Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. (2021) (77)
- Statistical Monitoring of Clinical Trials: A Unified Approach (2006) (76)
- Conducting Clinical Research During the COVID-19 Pandemic: Protecting Scientific Integrity. (2020) (71)
- Searching for evidence of altered gene expression: a comment on statistical analysis of microarray data. (1999) (71)
- Risk of infective endocarditis in mitral valve prolapse with and without precordial systolic murmurs. (1987) (64)
- Change in public perspective on cholesterol and heart disease. Results from two national surveys. (1987) (64)
- Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop (2012) (62)
- Safety and Reactogenicity of an MSP-1 Malaria Vaccine Candidate: A Randomized Phase Ib Dose-Escalation Trial in Kenyan Children (2006) (62)
- Interpreting Geographic Variations in Results of Randomized, Controlled Trials. (2016) (61)
- Applications of a Multinomial Capture-Recapture Model to Epidemiological Data (1974) (61)
- Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. (2003) (61)
- The Use of Interim Analysis for Sample Size Adjustment (1993) (60)
- Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. (2021) (60)
- Toward protecting the safety of participants in clinical trials. (2003) (59)
- Long‐term survival of participants in the CENTAUR trial of sodium phenylbutyrate‐taurursodiol in amyotrophic lateral sclerosis (2020) (58)
- Factorial designs in clinical trials: the effects of non-compliance and subadditivity. (1989) (56)
- 331. Note: On the Bias and Estimated Variance of Chapman's Two-Sample Capture-Recapture Population Estimate (1972) (55)
- Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) (2020) (53)
- Birth Order, Family Size and School Failure (1976) (53)
- Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group. (1999) (53)
- The estimation of false negatives in medical screening. (1978) (52)
- Immunity to influenza in older adults with chronic obstructive pulmonary disease. (2004) (51)
- Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators. (2001) (50)
- Behind closed doors: the data monitoring board in randomized clinical trials. (1993) (50)
- Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. (2009) (50)
- The Power of the Mantel—Haenszel Test (1987) (49)
- Late breaking clinical trials 1 (2011) (48)
- A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosum. (2005) (48)
- Quality control of dietary data collection in the CARDIA study. (1992) (48)
- A registry of patients with severe deficiency of alpha1-antitrypsin: Design and methods (1994) (47)
- Plasmodium falciparum circumsporozoite vaccine immunogenicity and efficacy trial with natural challenge quantitation in an area of endemic human malaria of Kenya. (1996) (46)
- Intent-to-treat analysis and the problem of crossovers. An example from the Veterans Administration coronary bypass surgery study. (1991) (45)
- Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. (1995) (45)
- Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. (1996) (44)
- Data monitoring committees: Promoting best practices to address emerging challenges (2017) (44)
- Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints (2019) (43)
- Digoxin–mortality: randomized vs. observational comparison in the DIG trial (2019) (43)
- Meta-analysis of CMVIG studies for the prevention and treatment of CMV infection in transplant patients. (1996) (43)
- Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board (2007) (42)
- Impact of a winter respiratory virus season on patients with COPD and association with influenza vaccination. (2006) (40)
- An Improved Double Sampling Procedure Based on the Variance (2000) (40)
- Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. (1990) (40)
- Combination chemotherapy in metastatic malignant melanoma. A randomized study of three DTIC‐containing combinations (1978) (39)
- The run-in period in clinical trials. The effect of misclassification on efficiency. (1990) (39)
- Effect of High-Dose Trivalent vs Standard-Dose Quadrivalent Influenza Vaccine on Mortality or Cardiopulmonary Hospitalization in Patients With High-risk Cardiovascular Disease: A Randomized Clinical Trial. (2020) (39)
- On looking at subgroups. (2009) (38)
- Recruitment in NHLBI population-based studies and randomized clinical trials: data analysis and survey results. (1987) (38)
- Cost-effectiveness of gemfibrozil for coronary heart disease patients with low levels of high-density lipoprotein cholesterol: the Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial. (2002) (38)
- Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical region (2005) (38)
- The use of subjective rankings in clinical trials with an application to cardiovascular disease. (1992) (38)
- High‐dose influenza vaccine to reduce clinical outcomes in high‐risk cardiovascular patients: Rationale and design of the INVESTED trial☆☆ (2018) (37)
- The power of the Mantel-Haenszel test for grouped failure time data. (1993) (37)
- Correlates, surrogates, and vaccines. (2007) (36)
- The data monitoring experience in the MOXCON trial. (2004) (36)
- Racial differences in outcome and treatment effect in congestive heart failure. (2005) (35)
- On Stopping a Randomized Clinical Trial for Futility (2012) (33)
- The high-risk myocardial infarction database initiative. (2012) (31)
- Liability issues for data monitoring committee members (2004) (29)
- Voluntary and involuntary capture-recapture samples--problems in the estimation of hidden and elusive populations. (1994) (29)
- Conduct of Clinical Trials in the Era of COVID-19 (2020) (28)
- Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline Summary. (2009) (27)
- Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial (2022) (27)
- Some practical problems in implementing randomization (2010) (26)
- Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. (2013) (23)
- Treatment of HF in an Era of Multiple Therapies: Statement From the HF Collaboratory. (2020) (23)
- On changing a long‐term clinical trial midstream (2002) (22)
- Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol (2000) (22)
- New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. (2016) (21)
- The impact of kidney function on outcomes following high risk myocardial infarction: findings from 27 610 patients (2014) (21)
- Intercept studies, clinical trials, and cluster experiments: to whom can we extrapolate? (1994) (21)
- Influence of beta blockade on exercise capacity and heart rate response after human orthotopic and heterotopic cardiac transplantation. (1989) (20)
- The FDA's Final Rule on Expedited Safety Reporting: Statistical Considerations (2015) (20)
- Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. (2007) (20)
- Preclinical Evaluation of a Chimeric Malaria Vaccine Candidate in Montanide ISA 720®: Immunogenecity and Safety in Rhesus Macaques (2006) (20)
- Missing Inaction: Preventing Missing Outcome Data in Randomized Clinical Trials (2009) (18)
- Clinical development strategy for a candidate group A streptococcal vaccine. (2017) (18)
- Some thoughts on sample size: A Bayesian-frequentist hybrid approach (2012) (18)
- Should we test for genotype in deciding on age-related eye disease study supplementation? (2015) (18)
- Sensitivity analysis using an imputation method for missing binary data in clinical trials (2001) (18)
- Testing the effect of treatment in experiments with correlated binary outcomes. (1992) (16)
- Stopping a trial early – and then what? (2012) (16)
- Bias and trials stopped early for benefit. (2010) (16)
- Ecology, pollution, environment (1972) (15)
- The Selection of Judges for Odor Discrimination Panels (1968) (14)
- Reports to Independent Data Monitoring Committees (2018) (14)
- Rank tests for survival analysis: a comparison by analogy with games. (1985) (14)
- Statistics with applications to the biological and health sciences: Richard D. Remington and M. Anthony Schork. Englewood Cliffs: Prentice-Hall, Inc., 1970. 355pp. Indexed. Price not available (1971) (14)
- Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the Systolic Hypertension in the Elderly Program (SHEP). (1997) (13)
- Terms of reference for Data and Safety Monitoring Committees. (2001) (13)
- Beware of on-treatment safety analyses (2018) (12)
- Analysis of data from clinical trials. (1983) (12)
- What information should a sponsor of a randomized trial receive during its conduct? (2011) (12)
- Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT): A Phase 3 Randomized Controlled Trial. (2016) (12)
- Reply to DS Kalman, MF McCarty, and V Juturu and JR Komorowski (2003) (11)
- Natural History of CLN2 Disease: Quantitative Assessment of Disease Characteristics and Rate of Progression (2016) (11)
- Preserved left ventricular function during supine exercise in patients after orthotopic cardiac transplantation. (1992) (11)
- Politically correct clinical trials. (1993) (11)
- Statistical considerations in monitoring the Systolic Hypertension in the Elderly Program (SHEP). (1992) (11)
- Monitoring the ACTIVE-W trial: some issues in monitoring a noninferiority trial. (2008) (11)
- Combination chemotherapy in metastatic malignant melanoma (1979) (10)
- Increased sensitivity of the denervated (10)
- Data monitoring in complex clinical trials: which treatment is better'? (1994) (10)
- On independent data monitoring committees in oncology clinical trials. (2014) (10)
- The treatment of missing data in a large cardiovascular clinical outcomes study (2016) (10)
- Experience collecting interim data on mortality: an example from the RALES study (2001) (10)
- Relation of Birth Order, Family Size and Social Class to Psychological Functions (1977) (9)
- The Evaluation of Medical Screening Procedures (1981) (9)
- Design and Analysis of Randomized Clinical Trials (2012) (9)
- Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. (1996) (9)
- Playing safe and preserving integrity: making the FDA model work (2004) (9)
- Why Is This Subgroup Different from All Other Subgroups? Thoughts on Regional Differences in Randomized Clinical Trials (2013) (9)
- On assessing the presence of evaluation‐time bias in progression‐free survival in randomized trials (2011) (8)
- First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES (2015) (8)
- Systolic hypertension in the elderly program (SHEP). X, Analysis (1991) (7)
- Clinical trials of the effectiveness of devices: an analogy with drugs. (2001) (7)
- Responsibilities of Data Monitoring Committees (2016) (7)
- Clinical trials must cope better with multiplicity (2012) (7)
- Outcome measures to assess efficacy of treatments for age-related macular degeneration. (2009) (7)
- Letter from the DSMC regarding a clinical trial of lutein in patients with retinitis pigmentosa. (2011) (7)
- Oat cell carcinoma of the lung: combination chemotherapy with cyclophosphamide, vincristine and procarbazine. (1977) (6)
- Forming Your Phase III Trial's Data and Safety Monitoring Board: A Perspective on Safety (2004) (5)
- Linear rank tests for survival data : equivalence of two formulations (1990) (5)
- Selecting screening criteria for clinical trials: an example from the Systolic Hypertension in the Elderly Program. (1999) (5)
- The Cross Trial Safety Analysis (2008) (5)
- Cardiovascular Safety and Efficacy of Vadadust for the Treatment of Anemia in Non-Dialysis Dependent CKD: Design and Baseline Characteristics. (2020) (5)
- INTRODUCTION : FROM CLINICAL TRIALS TO CLINICAL PRACTICE : FOUR PAPERS FROM A PLENARY SESSION (1994) (5)
- Times to event: why are they hard to visualize? (2008) (4)
- Systolic Hypertension of the Elderly Program (SHEP). Part 10: Analysis. (1991) (4)
- Comments on the FDA Draft Guidance on Adaptive Designs (2010) (4)
- Functional and Symptomatic Clinical Trial Endpoints: The HFC-ARC Scientific Expert Panel. (2022) (4)
- Discussion of Paper by Korn and Freidlin (2011) (4)
- University of Pennsylvania 10th annual conference on statistical issues in clinical trials: Current issues regarding data and safety monitoring committees in clinical trials (morning panel session) (2018) (4)
- Bias and Trials Stopped Early for Benefit. Authors' reply (2010) (4)
- [The Statistical Precision of Medical Screening Procedures: Application to Polygraph and AIDS Antibodies Test Data]: Comment (1987) (4)
- Part 10: Analysis (1991) (3)
- The authors reply [9] (2006) (3)
- Sentinel Event Methods for Monitoring Unanticipated Adverse Events (2007) (3)
- Data monitoring committee interim reports: We must get there soon! (2021) (3)
- Opening the Adaptive Toolbox (2006) (3)
- Simultaneous screening for three correlated lipids in the VA HDL Intervention Trial. (1999) (3)
- Randomized Treatment Assignment (2005) (3)
- The Influence of Biostatistics at the National Heart, Lung, and Blood Institute (2015) (2)
- Commentary on ‘Measurement in clinical trials: A neglected issue for statisticians?’ (2009) (2)
- SUBGROUP ANALYSIS OF CLINICAL TRIALS. REPLY (1991) (2)
- Geographic Variations in Controlled Trials. (2017) (2)
- Diethylstilbestrol in breast cancer: dose-response analysis. (1977) (2)
- Patiromer lowers serum potassium and prevents recurrent hyperkalemia in patients with heart failure and CKD when treated with RAAS inhibitors: Results from OPAL-HK (2015) (2)
- Dyslipoproteinemia in North America: The Lipid Research Clinics Program Prevalence Study. (1986) (2)
- The Use of Soft Endpoints in Clinical Trials: The Search for Clinical Significance (2002) (2)
- New statistical approach shows that hydroxy-methionine is noninferior to DL-Methionine in 35-day-old broiler chickens (2023) (2)
- Commentary on Randomization: The forgotten component of the randomized clinical trial (2018) (2)
- University of Pennsylvania ninth annual conference on statistical issues in clinical trials: Where are we with adaptive clinical trial designs? (afternoon panel discussion) (2017) (1)
- Effects of Frequent In-Center Hemodialysis: The Frequent Hemodialysis Network (FHN) Daily Trial (2010) (1)
- Discussion: M K B Parmar and David Machin, monitoring clinical trials; Experience of, and proposals under consideration by the Cancer Therapy Committee of the British Medical Research Council (1993) (1)
- Jerome Cornfield's contributions to early large randomized clinical trials and some reminiscences from the years of the slippery doorknobs (2012) (1)
- Commentary on Chirkova et al.: Some comments on “socialist pharmapolitics” (2021) (1)
- Cardiovascular risk associated with celecoxib - The authors reply (2005) (1)
- Randomized Clinical Trials in Heart Disease-Reply (1989) (1)
- Adhesion Evaluation of AG200-15: An Investigational Transdermal Contraceptive Delivery System (2019) (1)
- O62 – 1673 The natural history of late infantile CLN2 disease: striking homogeneity of clinical progression in two independently obtained large clinical cohorts (2013) (1)
- Calculation of the number of cis-trans isomers in a (1975) (1)
- Assessing correlates of protection in vaccine trials. (2014) (1)
- Commentary on Murray and Hernán (2016) (1)
- Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial (2023) (1)
- The Modern Randomized Clinical Trial: Is it Time to Sharpen a Blunt Instrument? (2019) (1)
- Differing approaches to analyse on-treatment cardiovascular events comparing daprodustat with darbepoetin: results from the ASCEND-ND trial (2022) (0)
- A Worksheet to Aid in Developing a DSMP (2004) (0)
- Response to letter to the editor titled: Noninferiority of the hydroxy analog of methionine compared to DL-methionine not confirmed in a broiler trial. (2023) (0)
- Chromium picolinate and type 2 diabetes. Authors' reply (2003) (0)
- A tale of three species – rabbits, chickens and humans: an interview with clinical trials pioneer Jeremiah Stamler (2006) (0)
- Some Aspects of the Application of Internal Pilot Studies (2006) (0)
- The Data Monitoring Committee: A Collective or a Collection? (2023) (0)
- Stopping the Randomized Aldactone Evaluation Study Early for Efficacy (2006) (0)
- Thoughts on A.B. Hill's Watson Lecture (2020) (0)
- Pazopanib versus sunitinib in renal cancer. (2013) (0)
- 169 Update on Enzyme Replacement Therapy (ERT) with Recombinant Human Arylsulfatase B (RHASB) for MPS VI (Maroteaux-Lamy) (2005) (0)
- Use of 5- (cid:1) -Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/ American Urological Association 2008 Clinical Practice Guideline (2009) (0)
- Author Response (2011) (0)
- Surrogate endpoint use in cardiovascular clinical trials (1986) (0)
- Daprodustat and On-Treatment Cardiovascular Events in Chronic Kidney Disease. Reply. (2022) (0)
- Roehrborn CG, Albertsen P, Stokes ME, Black L, Benedict A. First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer Prostatic Dis 2009. In press. (2009) (0)
- Mantel unhyphenated. (1999) (0)
- 25 th Annual Meeting of the Society for Clinical Trials Hyatt Regency Hotel, New Orleans, Louisiana Full Conference (2004) (0)
- Reading and Interpreting the Literature on Randomized Controlled Trials (2020) (0)
- Prior publication on monitoring clinical trials. (1988) (0)
- A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, CONTROLLED DOSE COMPARISON OF THALIDOMIDE FOR TREATMENT OF ERYTHEMA (2005) (0)
- Prevalence of Unknown Parental History of Disease in Either or Both Parents Prevalence of unknown history ( % ) Race Mother Father Both Disease group only only parents Hypertension Black (2005) (0)
- Experiences of the Data Monitoring Committee for the RECOVERY trial, a large-scale adaptive platform randomised trial of treatments for patients hospitalised with COVID-19 (2022) (0)
- Multistage screening for entry into clinical trials (1992) (0)
- Comment on paper by Crowe et al (2009) (0)
- Sample Sizes for Clinical Trials by JULIOUS, S. A. (2012) (0)
- Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents - post hoc analyses of the ASCEND-ND and ASCEND-D trials. (2022) (0)
- Subgroups time to change the question? (2000) (0)
- Clinical Trials in Neurology: Fundamentals of Biostatistics (2012) (0)
- University of Pennsylvania 5th annual conference on statistical issues in clinical trials: Emerging statistical issues in biomarker validation (Morning Session) (2013) (0)
- Plans for analysis of the shep trial (1990) (0)
- Adaptive Designs in Clinical Trials (2005) (0)
- Glucose and insulin responses to dietary chromium supplements: a meta-analysis 1–3 (2002) (0)
- Making Independence Work: Monitoring the Bevacizumab Colorectal Cancer Clinical Trial (2006) (0)
- FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL (2022) (0)
- Abstract 4706: Perfusion Stress Echocardiography with Perflubutane Polymer Microspheres Provides Incremental Predictive Value for Coronary Artery Disease Over Clinical Risk Factors (2008) (0)
- Wittes On Looking at Subgroups 913 (2009) (0)
- inappropriate methods Digitalis--a new controversy regarding an old drug. The pitfalls of (2011) (0)
- Ten Most Commonly Asked Questions about Statistical Analysis of Clinical Trials (1999) (0)
- Multistage screening for a lipid-restricted population: The VA HDL intervention trial (HIT) (1992) (0)
- Case 19: Data Monitoring Experience in the Moxonidine Congestive Heart Failure Trial (2006) (0)
- Intent-to-treat analysis: Reply to the Editor (1992) (0)
- Discussion: Is FDA in need of a major change in the way it regulates? (2017) (0)
- Panel discussion of case study 2 (2005) (0)
- THE USE OF SUBJECTIVE RANKINGS IN CLINICAL TRIALS WITH AN APPLICATION TO CARDIOVASCUALR DISEASE. COMMENTS (1992) (0)
- Book Review: JM Gueron and H Rolston 2013: Fighting for reliable (2014) (0)
- P65 Considerations for a group sequential, dose-response trial design (1993) (0)
This paper list is powered by the following services:
Other Resources About Janet Wittes
What Schools Are Affiliated With Janet Wittes?
Janet Wittes is affiliated with the following schools:
